الرئيسية › سرطان الرئة غير صغير الخلايا › ماريلاند › Baltimore
التجارب السريرية لـ سرطان الرئة غير صغير الخلايا في Baltimore، MD
60 دراسات لـ سرطان الرئة غير صغير الخلايا تبحث عن مشاركين في مواقع داخل وحول Baltimore (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
جارٍ التسجيلالمرحلة 3
- Greater Baltimore Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- و 4 أخرى
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 2
- Local Institution - 0123, Baltimore
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
جارٍ التسجيلالمرحلة 3
- Ascension Saint Agnes Hospital, Baltimore
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 1/2
- Research Site, Baltimore
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
جارٍ التسجيلالمرحلة 1
- Exelixis Clinical Site #14, Baltimore
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
جارٍ التسجيلالمرحلة 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 2
- Johns Hopkins University, Baltimore
DK222 Study at Hopkins
جارٍ التسجيلالمرحلة 1
- Johns Hopkins Hospital, Baltimore
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
جارٍ التسجيلالمرحلة 3
- Johns Hopkins University of Medicine, Baltimore
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 2
- Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 3
- Maryland Oncology Hematology, P.A., Annapolis · على بُعد 22 ميل
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Research Site, Towson · على بُعد 8 ميل
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Maryland Oncology Hematology, P.A., Annapolis · على بُعد 22 ميل
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 2
- University of Maryland, Baltimore
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 2
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- University of Maryland, Baltimore
- Johns Hopkins Bayview Medical Center, Baltimore
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
جارٍ التسجيلالمرحلة 3
- Research Site, Annapolis · على بُعد 22 ميل
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 2
- Research Site, Baltimore
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
جارٍ التسجيلالمرحلة 3
- Local Institution - 0505, Annapolis · على بُعد 22 ميل
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
جارٍ التسجيلالمرحلة 3
- Local Institution - 0702, Annapolis · على بُعد 22 ميل
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
جارٍ التسجيلالمرحلة 2
- University of Maryland Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Medstar Franklin Square, Baltimore
- و 1 أخرى
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
جارٍ التسجيلالمرحلة 3
- Clinical Study Site, Baltimore
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1
- Johns Hopkins, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
جارٍ التسجيلالمرحلة 1
- United Theranostics, Glen Burnie · على بُعد 9 ميل
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
جارٍ التسجيلالمرحلة 2/3
- The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
جارٍ التسجيلالمرحلة 2
- John Hopkins Medical Center, Baltimore
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Johns Hopkins Bayview Medical Center, Baltimore
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
جارٍ التسجيلالمرحلة 3
- Research Site, Baltimore
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1
- University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
جارٍ التسجيلالمرحلة 3
- University of Maryland, Baltimore
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
جارٍ التسجيلالمرحلة 2
- MedStar Franklin Square Medical Center ( Site 0033), Baltimore
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
جارٍ التسجيلالمرحلة 3
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
جارٍ التسجيلالمرحلة 1/2
- Johns Hopkins University, Baltimore
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
جارٍ التسجيلالمرحلة 1
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- Sidney Kimmel Comprehensive Cancer at Johns Hopkins, Baltimore
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
جارٍ التسجيلالمرحلة 1/2
- University of Maryland, Baltimore
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
جارٍ التسجيلالمرحلة 2
- Research Site, Baltimore
GCC 2546- Motion Management
جارٍ التسجيل
- University of Maryland Greenebaum Cancer Center, Baltimore
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
جارٍ التسجيلالمرحلة 1
- Advanced Molecular Imaging and Therapy, Glen Burnie · على بُعد 9 ميل
- United Theranostics - Chesapeake, Glen Burnie · على بُعد 9 ميل
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
جارٍ التسجيلالمرحلة 1
- Johns Hopkins Hospital /ID# 254056, Baltimore
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · على بُعد 9 ميل
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
جارٍ التسجيلالمرحلة 1
- Johns Hopkins University, Baltimore
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
جارٍ التسجيلالمرحلة 1/2
- Johns Hopkins Hospital, Baltimore
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
جارٍ التسجيلالمرحلة 1/2
- Johns Hopkins University, Baltimore
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 3
- Research Site, Baltimore
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
جارٍ التسجيلالمرحلة 1
- Maryland Proton Treatment Center, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore
- Baltimore Washington Medical Center- Tate Cancer Center, Glen Burnie · على بُعد 9 ميل
- و 1 أخرى
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2/3
- Saint Agnes Hospital, Baltimore
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · على بُعد 9 ميل
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
جارٍ التسجيلالمرحلة 2
- Kaiser Permanente-Woodlawn Medical Center, Baltimore
- Kaiser Permanente Lutherville - Timonium Medical Center, Lutherville · على بُعد 9 ميل
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 2
- University of Maryland Medical Center, Baltimore
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Johns Hopkins University, Baltimore
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
جارٍ التسجيلالمرحلة 1
- Research Site, Baltimore
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
جارٍ التسجيلالمرحلة 1
- Johns Hopkins University, Baltimore
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
جارٍ التسجيلدراسة رصدية
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- UM Saint Joseph Medical Center, Towson · على بُعد 8 ميل
- و 1 أخرى
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
جارٍ التسجيلالمرحلة 2
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore
- Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
جارٍ التسجيل
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore
GEMINI-NSCLC: NSCLC Biomarker Study
جارٍ التسجيلدراسة رصدية
- University of Maryland, Baltimore
- Johns Hopkins University, Baltimore
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
جارٍ التسجيلدراسة رصدية
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Towson · على بُعد 8 ميل
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
جارٍ التسجيلالمرحلة 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
تجارب سرطان الرئة غير صغير الخلايا في مدن أخرى
- Houston, TX145 دراسات
- New York City, NY121 دراسات
- Arlington, VA104 دراسات
- Nashville, TN97 دراسات
- Boston, MA90 دراسات
- Los Angeles, CA87 دراسات
- St. Louis, MO73 دراسات
- Chicago, IL61 دراسات
- San Antonio, TX59 دراسات
- Columbus, OH57 دراسات
- Washington, DC55 دراسات
- Seattle, WA53 دراسات
دراسات أخرى في Baltimore
- سرطان الثدي47 دراسات
- سرطان البروستاتا43 دراسات
- سرطان الرئة40 دراسات
- السرطان (جميع الأنواع)37 دراسات
- سرطان البنكرياس31 دراسات
- سرطان القولون والمستقيم31 دراسات
- السرطان النقيلي28 دراسات
- السمنة26 دراسات
- سرطان المثانة24 دراسات
- قصور القلب24 دراسات
- سرطان المبيض22 دراسات
- السكتة الدماغية21 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 06/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.